Implications of comparative effectiveness research for radiation oncology

被引:21
作者
Bekelman, Justin E. [1 ,2 ]
Shah, Anand [1 ]
Hahn, Stephen M. [1 ]
机构
[1] Univ Penn, Abramson Canc Ctr, Dept Radiat Oncol, 3400 Spruce St,2 Donner, Philadelphia, PA 19104 USA
[2] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/j.prro.2011.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The essence of comparative effectiveness research (CER) is to understand what health interventions work, for which patients, and under what conditions. The objective of this article is to introduce the relative strengths and weaknesses of several forms of evidence to illustrate the potential for CER evidence generation within radiation oncology. Methods: We introduce the underlying concepts of effectiveness and efficacy. We describe the design of traditional explanatory randomized trials (RCTs). We introduce the rationale, strengths, and weaknesses of several alternative study designs for comparative effectiveness, including pragmatic clinical trials, adaptive trials, and observational (nonrandomized) studies. Results: Explanatory RCTs are designed to assess the efficacy of an intervention while achieving a high degree of internal validity. Pragmatic clinical trials (PCTs) are prospective studies performed in typical, real-world clinical practice settings. The emphasis of PCTs is to maintain a degree of internal validity while also maximizing external validity. Adaptive trials can be modified at interim stages using existing or evolving evidence in the course of a trial, which may allow trials to maintain clinical relevance by studying current treatments. Observational data are becoming increasingly important, given substantial funding for clinical registries and greater availability of electronic medical records and claims databases, but need to address well-known limitations such as selection bias. Conclusion: With the rapid proliferation of new and evolving radiotherapy technologies, it is incumbent upon our field to invest in building the evidence base for radiotherapy CER and to actively participate in current initiatives for generating comparative evidence. (C) 2011 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 76 条
[1]
Abe O, 2005, LANCET, V366, P2087
[2]
Electronic Patient-Reported Data Capture as a Foundation of Rapid Learning Cancer Care [J].
Abernethy, Amy P. ;
Ahmad, Asif ;
Zafar, S. Yousuf ;
Wheeler, Jane L. ;
Reese, Jennifer Barsky ;
Lyerly, H. Kim .
MEDICAL CARE, 2010, 48 (06) :S32-S38
[3]
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort [J].
Albertsen, Peter C. ;
Hanley, James A. ;
Penson, David F. ;
Barrows, George ;
Fine, Judith .
JOURNAL OF UROLOGY, 2007, 177 (03) :932-936
[4]
[Anonymous], 2009, IN NAT PRIOR COMP EF
[5]
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy [J].
Barker, A. D. ;
Sigman, C. C. ;
Kelloff, G. J. ;
Hylton, N. M. ;
Berry, D. A. ;
Esserman, L. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) :97-100
[6]
Use of instrumental variables in the presence of heterogeneity and self-selection: An application to treatments of breast cancer patients [J].
Basu, Anirban ;
Heckman, James J. ;
Navarro-Lozano, Salvador ;
Urzua, Sergio .
HEALTH ECONOMICS, 2007, 16 (11) :1133-1157
[7]
Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer [J].
Bekelman, Justin E. ;
Zelefsky, Michael J. ;
Jang, Thomas L. ;
Basch, Ethan M. ;
Schrag, Deborah .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05) :1456-1466
[8]
An introduction to causal modelling in clinical trials [J].
Bellamy, Scarlett L. ;
Lin, Julia Y. ;
Have, Thomas R. Ten .
CLINICAL TRIALS, 2007, 4 (01) :58-73
[9]
Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer [J].
Bentzen, SM ;
Bernier, J ;
Davis, JB ;
Horiot, JC ;
Garavaglia, G ;
Chavaudra, J ;
Johansson, KA ;
Bolla, M .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (05) :615-620
[10]
Berenson A, 2008, NY TIMES